Home > Drugs A – Z > Brinzolamide (Into the eye)

Brinzolamide (Into the eye)

Treats increased eye pressure caused by glaucoma or ocular hypertension.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Brinzolamide ophthalmic (eye) drops is used to treat increased pressure in the eye caused by open-angle glaucoma or a condition called ocular hypertension. Both eye conditions are caused by high pressure in your eye and can lead to pain from pressure in your eye and then can eventually harm your vision. This medicine can help you keep your sight by reducing the pressure in your eye and stopping… Read more
Brand names include
Azopt, Azopt 1%
Drug classes About this
Antiglaucoma
Combinations including this drug

What works? Research summarized

Evidence reviews

Brinzolamide plus brimonidine for the treatment of glaucoma: an update

INTRODUCTION: Glaucoma is a common sight-threatening condition that is primarily treated by lowering intraocular pressure (IOP). Today the mainstay of treatment is topical ocular hypotensive medications; many patients require more than one agent to achieve target IOP. For such patients, fixed combination formulations have several advantages including simplicity of treatment regimen, adherence to the treatment regimen, efficacy, improved ocular surface comfort and reduced cost. All currently available fixed combinations contain a β-blocker, which is contraindicated in some patients. Hence there is a clinical need for fixed-combination preparations without a β-blocker. This paper reviews the current literature on a new fixed-combination drug containing brinzolamide 1% and brimonidine 0.2% (BBFC).

Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension

This guideline covers adults (18 and older) with a diagnosis of chronic open angle glaucoma or ocular hypertension and those with chronic open angle glaucoma or ocular hypertension associated with pseudoexfoliation or pigment dispersion. In addition, the guideline will cover populations who have a higher prevalence of glaucoma and may have worse clinical outcomes including people with a family history of glaucoma, younger people (<50 years) and people who are of black African or black Caribbean descent. Options for pharmacological, surgical, laser and complimentary or alternative treatments are considered in terms of clinical effectiveness and cost effectiveness.

Meta-analysis of alpha2-adrenergic agonists versus carbonic anhydrase inhibitors as adjunctive therapy

The review concluded that brimonidine provided greater intraocular lowering efficacy than topical anhydrase inhibitors as adjunctive therapy to beta blockers or prostaglandin analogues in patients with glaucoma or ocular hypertension. The review was unable to rule out the possibility of publication bias and there was substantial heterogeneity in the overall analyses so the authors' conclusions should be considered tentative.

See all (7)

PubMed Health Blog...

read all...